Skip to main content
. Author manuscript; available in PMC: 2022 Jun 1.
Published in final edited form as: Br J Haematol. 2021 May 24;193(6):1142–1150. doi: 10.1111/bjh.17534

Figure 4.

Figure 4.

A. Men have significantly higher number of somatic mutations in high-risk genes across the entire cohort (P=0.009) with a more prominent difference among CMML patients. B. Kaplan-Meier analysis showing the cumulative survival of men with and without EZH2 mutation including patients with MDS/MPN-U, CMML and aCML. Men with EZH2 mutation have significantly worse survival (P=0.034) compared to men without EZH2 mutation. C. Competing-risk regression analysis showing the cumulative incidence of transformation to AML among men with and without EZH2 mutation including patients with MDS/MPN-U, CMML and aCML. Men with EZH2 mutation appear to have higher incidence of transformation to AML but difference was not significant (P=0.465).